Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension

NCT05516498 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05516498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05516498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2022
Completion date
July 17, 2025
Enrollment
205 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

liver cirrhosis